Efficacy of cefepime therapy for Enterobacter bacteraemia, with special emphasis on febrile neutropenic patients

Scandinavian Journal of Infectious Diseases

Volumn 42, Issue 6-7, 2010, Pages 557-559

  Lee, Jeong A ^a   Kang, Cheol In ^a   Joung, Mi Kyong ^a   Moon, Soo Youn ^a   Chung, Doo Ryeon ^a   Ko, Kwan Soo ^a   Peck, Kyong Ran ^a   Song, Jae Hoon ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BETA LACTAMASE AMPC; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; EXTENDED SPECTRUM BETA LACTAMASE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; CANCER PATIENT; CATHETER INFECTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; ENTEROBACTER; ENTEROBACTERIACEAE INFECTION; ESCHERICHIA COLI; FEBRILE NEUTROPENIA; FEMALE; GRAM NEGATIVE SEPSIS; HUMAN; KLEBSIELLA PNEUMONIAE; LETTER; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; URINARY TRACT INFECTION; BACTEREMIA; DRUG EFFECTS; ENTEROBACTERIACEAE INFECTIONS; FEVER; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; NEUTROPENIA; TREATMENT OUTCOME; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BACTEREMIA; CEPHALOSPORINS; ENTEROBACTER; ENTEROBACTERIACEAE INFECTIONS; FEMALE; FEVER; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NEUTROPENIA; TREATMENT OUTCOME;

EID: 77953265682     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365541003621528     Document Type: Letter

References (7)

1. Sanders WE Jr, Tenney JH, Kessler RE. Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species. Clin Infect Dis 1996;23:454-461
2. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-751
3. Pai H, Hong JY, Byeon JH, Kim YK, Lee HJ. High prevalence of extended-spectrum beta-lactamase-producing strains among blood isolates of Enterobacter spp. collected in a tertiary hospital during an 8-year period and their antimicrobial susceptibility patterns. Antimicrob Agents Chemother 2004;48: 3159-3161
4. Yahav D, Paul M, Fraser A, Sarid N, Leibovici L. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis 2007;7:338-348
5. Goethaert K, Van Looveren M, Lammens C, Jansens H, Baraniak A, Gniadkowski M, et al. High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients. Clin Microbiol Infect 2006;12:56-62.
6. Thomson KS, Moland ES. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extendedspectrum beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2001;45:3548-3554
7. Kang CI, Pai H, Kim SH, Kim HB, Kim EC, Oh MD, et al. Cefepime and the inoculum effect in tests with Klebsiella pneumoniae producing plasmid-mediated AmpC-type betalactamase. J Antimicrob Chemother 2004;54:1130-1133